Toward Completion of the Human Proteome Parts List: Progress Uncovering Proteins That Are Missing or Have Unknown Function and Developing Analytical Methods. by Paik, Young-Ki et al.
Providence St. Joseph Health
Providence St. Joseph Health Digital Commons
Articles, Abstracts, and Reports
12-7-2018
Toward Completion of the Human Proteome Parts
List: Progress Uncovering Proteins That Are
Missing or Have Unknown Function and
Developing Analytical Methods.
Young-Ki Paik
Christopher M Overall
Fernando Corrales
Eric W Deutsch
Institute for Systems Biology, Seattle, WA, USA.
Lydie Lane
See next page for additional authors
Follow this and additional works at: https://digitalcommons.psjhealth.org/publications
Part of the Genetics and Genomics Commons
This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has been accepted for inclusion in Articles,
Abstracts, and Reports by an authorized administrator of Providence St. Joseph Health Digital Commons. For more information, please contact
digitalcommons@providence.org.
Recommended Citation
Paik, Young-Ki; Overall, Christopher M; Corrales, Fernando; Deutsch, Eric W; Lane, Lydie; and Omenn, Gilbert S, "Toward
Completion of the Human Proteome Parts List: Progress Uncovering Proteins That Are Missing or Have Unknown Function and
Developing Analytical Methods." (2018). Articles, Abstracts, and Reports. 1471.
https://digitalcommons.psjhealth.org/publications/1471
Authors
Young-Ki Paik, Christopher M Overall, Fernando Corrales, Eric W Deutsch, Lydie Lane, and Gilbert S
Omenn
This article is available at Providence St. Joseph Health Digital Commons: https://digitalcommons.psjhealth.org/publications/1471
Toward Completion of the Human Proteome Parts List: Progress
Uncovering Proteins That Are Missing or Have Unknown Function
and Developing Analytical Methods
For the past 6 years, the Journal of Proteome Research hassupported the Human Proteome Organization (HUPO)
in dedicating a special issue of the journal to the Chromosome-
centric Human Proteome Project (C-HPP); for the past 2
years, it has encompassed the whole HPP with contributions
also from the Biology/Disease (B/D)-HPP and the HPP
resource pillars. The 32 papers published this month further
annotate the human protein parts list or present advances in
analytical methods for the identification of proteoforms or new
members of the human proteome. This Editorial presents
highlights of selected papers that focus on the increasingly
difficult task for the C-HPP international teams of identifying
the remaining unannotated proteins in the human proteome
that lack evidence of existence at the protein level (PE1) but
have less direct evidence of their existence (PE2,3,4), the so-
called missing proteins (MPs) in neXtProt. In total, 104 MPs
have been found that meet the stringent HPP guidelines
designed to mitigate against false discovery and incorrect
annotation in neXtProt and other public databases (Table 1).
In addition, 107 MPs identified in the MassIVE database will
be processed through the Trans-Proteomic Pipeline of
PeptideAtlas for submission to neXtProt. Many credible
detections of MPs are only possible from analyses of rare or
uncommonly analyzed cells and tissues, which often necessitate
innovative sample preparation and data analysis workflows. Six
papers present strategies and findings on the functionalization
of some of the ∼1260 uncharacterized “dark proteins” (uPE1)
lurking in the human proteome yet lacking any experimentally
determined or predicted function. Other papers report
biomarker discovery, analyses of protein variants, glycan and
other post-translational modifications (PTMs), and the
mitochondrial database, proteome, and N-terminome (Figure
1). In summary, this Special Issue marks major advances in the
journey toward completion of the human proteome parts list in
the context of proteome biology and disease; while
tantalizingly near, this global journey must still overcome
formidable challenges to complete the first accurate draft of the
human proteome.
■ PROGRESS ON THE CREDIBLE DETECTION OF
neXtProt PE2,3,4 MISSING PROTEINS
In the category of MPs, 14 papers present topics ranging from
overall metrics for the Human Proteome and results from MS
analyses of under-studied cells, organelles, or tissues to the
application of novel or useful analytical methods. Omenn et
al.1 update the status of 17 470 credibly identified PE1 proteins
in the neXtProt release 2018-01-17, including 462 previous
MPs as of release 2017-01-23. This represents an authoritative
2018 draft of the human proteome. These PE1 proteins can be
divided into two groups reflecting the method of identification:
16 092 proteins from MS analyses and 1378 proteins from
other methods (protein−protein interactions, disease muta-
tions, PTM and proteolytic processing, 3D structures, Edman
degradation, antibody-based techniques, and other biochemical
approaches). Meanwhile, PeptideAtlas expanded its count of
canonical proteins by 625, including 269 from a single study of
SUMOylation. The number of MPs has dropped from 5511 in
2012, to 2949 in 2016, to 2186 in the 2018-01 releases from
neXtProt.
A major strategy to detect the expression of MPs is the
analysis of under-studied or rare tissue specimens (Figure 1).
Examples here are cerebrospinal fluid (CSF), olfactory
epithelium, human mesenchymal stem cells (hMSCs) from
adipose tissue, and human embryonic stem cells (hESCs).
Macron et al.2 of the Swiss Chromosome 2 team analyzed a
commercial pool of CSF samples and identified 2281 proteins
according to the stringent HPP guidelines;3 two PE2 proteins,
augurin (Q9H1Z8) and shadow of prion protein (Q5BIV9),
were identified from five and two uniquely mapping peptides
of at least nine amino acids (aa) in length, respectively, and
then confirmed using spectra of their cognate synthetic
peptides. For 14 additional MPs, there was only one such
peptide; however, a second uniquely mapping “stranded
peptide” was found in PeptideAtlas for 5 of these, making a
total of 7 MPs with good spectra. Four of these proteins are
exclusively or mostly expressed in brain. The same authors4
performed a “deep dive” on a different pool of normal CSF
specimens, detecting 3379 proteins overall and 12 MPs,
including 3 transmembrane protocadherins; 8 were based on
2−6 uniquely mapping peptides, whereas 4 more had a single
peptide that was combined with a stranded peptide in
PeptideAtlas from previous CSF data sets. However, 6 were
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Table 1. List of Papers Presenting the Discovery of Credible
Missing Proteins in This Issue
article in this issue
number of MPs and their cell or tissue source
meeting HPP Guidelines v 2.10
Macron et al.2,4 13 cerebrospinal fluid
Clemente et al.7 1 mesenchymal stem cells
He et al.17 2 mirror proteases
Hwang et al.5 5 olfactory epithelium
Robin et al.10 1 HeLa cells
Ronci et al.11 3 mitochondria
Sun et al.16 14 multiple proteases
Weldemariam et al.8 26 embryonic stem cells
Zhang et al.9 30 membrane proteins
Sjöstedt et al.6 9 skin, retina, thymus, pituitary, hypothalamus, and
lactating breast
Pullman et al.32 107 MassIVE database
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already found in the first Macron et al. paper,2 so the combined
total of newly found MPs from CSF is 13.
For years, we have yearned for samples of olfactory
epithelium to seek the expression of some of the 404 predicted
proteins from olfactory receptor genes. Hwang et al.5 from
Korea identified 3731 proteins, among which were five MPs
(P0C7M7, P46721, P59826, Q658L1, Z8N434) previously
identified only by mRNA (PE2) and validated with synthetic
peptides in a trans-sphenoidal surgical sample of ethmoid
mucosa of the nasal cavity in a patient with meningioma of the
anterior skull base. The MPs met the HPP Guidelines v2.1.0,3
requiring two uniquely mapping and non-nested peptides of at
least 9 aa, confirmed with the neXtProt uniqueness checker.
Sadly, none were olfactory receptor proteins. However,
P59826 (BPIFB3, BPI fold-containing family B member 3) is
annotated in neXtProt as recognizing and binding specific
classes of odorants, acting as a carrier molecule transporting
odorants across the mucus layer to access receptor sites.
BPIFB3 transcripts were expressed in the olfactory epithelium
at 10 times the levels in 17 control tissues. The authors also
identified 50 splice isoforms and 2000 single aa sequence
variants.
Sjöstedt et al.,6 from the Human Protein Atlas and the HPP
Antibody Profiling resource pillar, introduce tissue profiling
with a combination of transcription and protein expression/
localization with immunohistochemistry to identify MPs in
skin and five understudied tissue types: retina, thymus,
pituitary, hypothalamus, and lactating breast. Transcription
data were available from HPA, the GTEx consortium, and the
FANTOM5 consortium to identify genes selectively expressed
in specialized tissues. With this workflow, which went well
beyond standard tissue microarray assays, the authors verified
targets that showed enhanced or enriched expression in certain
tissues and their histological structures with antibody (Ab)-
based proteomics techniques. Among the 300 proteins sought,
9 MPs were detected and localized: POU4F1, FRMD1,
ARHGEF33, GABRG1, KRTAP2-1, BHLHE22, SPRR4,
AVPR1B, and DCLK3. This approach could be enhanced by
adding MS/MS analyses of the same specimens.
Clemente et al.,7 the Chromosome 16 team from Spain,
present proteomic profiling of about 6000 proteins (false
discovery rate (FDR) 1%) from ten million hMSCs derived
from adipose tissue or umbilical cord using RP-QTOF or
PAGE-Q Exactive analyses. They identified peptides from 13
MPs after filtering with the neXtProt uniqueness checker. Only
one had more than a single unique peptide; they showed
compelling evidence of the expression of hyaluronan synthase
1 (Q92839-1), with four peptides of 9+ aa and coelution of
heavy-labeled synthetic peptides for three of them. The one
peptide that was not confirmed, due to different retention time,
was attributed to the reverse sequence of −LV− from a
different protein. It is surprising that this membrane-localized
enzyme with seven transmembrane regions was an MP, as
hyaluronan is a well-studied and critical extracellular matrix
component, especially in cartilage. The additional 12 proteins
reserved for further analysis may be good prospects. For 3 of
these 12 proteins (Q6TDP4-1, Q3ZCT8-1, Q96HZ4-2), they
found a stranded uniquely mapping second peptide in
PeptideAtlas, and they are now pursuing their confirmation
with synthetic peptides and selected reaction monitoring
(SRM) approaches.
Weldemariam et al.8 of the Chromosome 4 team from
Taiwan performed subcellular analyses of membrane proteins
from hESCs using their reported two-step centrifugation with
sucrose to obtain nuclear, cytoplasmic, and membrane
fractions, followed by gel-assisted digestion with trypsin,
peptide fractionation, and LC−MS/MS analysis. According
to the 2018-01-17 release from neXtProt, membrane proteins
represent 48% of the 2186 PE2,3,4 MPs. This paper reports
11 970 unique proteins with 1% protein FDR, including 6138
membrane proteins, with 26 PE2,3,4 MPs meeting HPP
Guidelines and 21 verified by MRM−MS or matching spectra
Figure 1. Overall flow of research works presented in this Special Issue. The “Input” part is composed of metrics for counting missing proteins, the
updated release of neXtProt proteome information, and various cell-type RNA-Seq databases. Annotation strategies cover several components that
can be developed or upgraded, leading to the production of various deliverables as outputs. Abbreviations used here: ASVs, alternative spliced
variants; PE, protein evidence or existence; PPI, protein−protein interaction; TPP, Trans-Proteomic Pipeline; uPE1, uncharacterized PE1.
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from synthetic peptides in PeptideAtlas. The identification of
these MPs and their further analysis revealed potential roles in
pluripotency-related pathways and lineage- and tissue-specific
differentiation. GPR19 was highlighted as the most positively
significant gene association for the maintenance or differ-
entiation of hESCs. Single unique peptides for 87 MPs were
detected, so the stranded peptide approach could be applied.
They also prepared to address the uPE1/neXt-CP50 challenge,
noting the identification of 570 uPE1 proteins, of which 28
were coded on Chromosome 4.
Zhang et al.9 used a hydrophobic peptide separation
workflow to identify membrane-associated MPs and found
30 MPs (≥2 non-nested unique peptides with ≥9 amino acids)
from the membrane preparations of K562 and HeLa cell lines
and human placenta. Nineteen of the 30 were categorized as
membrane proteins or extracellular matrix proteins. Robin et
al.10 reanalyzed 41 publicly available HeLa cell data sets, using
a custom-made quantitative spectral counting approach to find
just 1 MP candidate (FRAT2) plus 189 new phosphorylation
sites, 392 N-terminal acetylation sites, and 21 SAAVs. Ronci et
al.11 reported a sequential fractionation strategy that identified
and verified three low-abundance nuclear-coded MPs
(METTL12, FAM163A, RGS13) in mitochondria from five
cell line samples after filtering with the neXtProt uniqueness
checker; no MP candidates were found with HeLa cells. The
lack of MPs remaining to be identified in HeLa cells is not
surprising because these cells are one of the most commonly
used and well-studied over the years.
A very productive line of investigation over the past few
years has been the exploitation of knowledge that transcript
expression is highest for nearly 1000 protein-coding genes in
the male reproductive tract. Hundreds of PE2,3,4 MPs have
been detected in sperm and testis, led by the Chromosome 2/
14 consortium in Switzerland and France12,13 and the
Chromosome 1 team in China.14,15 Sun et al.16 identified
11 558 proteins in testis using SDS-PAGE fractionation,
digestion with a combination of the proteases trypsin, LysC,
and GluC, and high-pH reverse-phase fractionation; this total
is 3700 more proteins than the previous year.15 They identified
114 MP candidates and verified 14 with 2 unique peptides of at
least 9 aa by spectrum quality checking, isobaric PTM and
SAAV filtering, and synthesized peptide matching. Of the 14
MPs, 3 were testis-specific proteins and 10 were closely related
to liver cancer, potentially useful for biomarker development in
hepatocellular carcinoma. He et al.17 used the “mirror
protease” approach, whereby the new protease LysargiNase
(Huesgen et al.),18 which cleaves N-terminal to lysine and
arginine and so mirrors trypsin (cutting C-terminal to lysine
and arginine), was used with Tricine-SDS-PAGE enrichment
for low-molecular-weight (LMW) proteins and identified 4063
proteins and 2565 LMW (<40 kDa) proteins, of which 1130
had paired peptides generated from the two proteases. Among
seven MP candidates, they verified two with a series of
continuous and complementary b/y-product ions in the paired
spectra: beta-defensin 123 (Q8N688) and C17orf64
(Q86WR6). C17orf64 was independently prioritized by
Siddiqui et al.19 for detection on Chr 17 (below). The other
five have only one proteotypic peptide and require further
verification. Attention to LMW proteins may be wise because
there is a much higher proportion of MPs to PE1 proteins
when the MW is <40 kDa.
An example for all of the HPP chromosome teams is the
analysis by Siddiqui et al.19 of the basis for progress toward the
October 2016 neXt-MP50 challenge for Chromosome 17. The
number of MPs from Chr 17 was reduced from 148 in
neXtProt 2016-01 to 105 in neXtProt 2018-01. The evidence
of PE1 was by mass spectrometry for 25, protein−protein
interaction for 12, a combination of the two approaches for 3,
and other methods for the remaining 3, across the global
proteomics community. Notable among these new PE1
proteins were five keratin-associated proteins, a single olfactory
receptor, and five additional membrane-embedded proteins.
The Chr 17 team then evaluated the remaining 105 MPs for
the best prospects, of which 88 are PE2 with transcript data.
All but 16 have 2 or more potential proteotypic sequences of at
least 9 aa. They identified the top 10 and next 15 for MS and
the top 10 for protein−protein interaction assays. One MS
candidate was confirmed by finding a matching stranded
peptide in PRIDE. Two ranked among the top 10 MS
candidates have been reported in this Special Issue, RNF112
by Macron et al.2 in CSF and C17orf64 by He et al.17 in testis,
adding further comfort to their confident identification. These
3 found MPs will move Chr 17 to at least 46 MPs found when
the neXtProt 2019-01 version is released. The discussion notes
the importance of evaluating the use of recombinant baits in
yeast two-hybrid assays that drive the verification of some of
the proteins classified as PE1 based on protein−protein
interactions.
■ PROTEOME ANNOTATION AND STUDIES OF uPE1
PROTEINS LACKING FUNCTIONAL ANNOTATION
IN neXtProt
As a new avenue toward the completion and annotation of the
human protein parts list, in March 2018, the HUPO C-HPP
consortium launched neXt-CP50, in which CP stands for
“characterization of protein” and uPE1 refers to the
uncharacterized PE1 proteins in neXtProt. neXtProt utilizes
both experimental and informatics evidence of functional
annotation. In March 2018, neXtProt provided a list of 1260
proteins identified with high confidence at the protein level
(PE1) but considered as functionally uncharacterized, that is,
without any functional annotation or solely annotated with
generic GO terms that are not linked to any specific function,
such as protein binding, calcium binding, zinc binding, metal
ion binding, identical protein binding, protein homo-
oligomerization, or signal transduction. The neXt-CP50
project aims to characterize an initial 50 of these 1260 uPE1
proteins in 3 years. Paik et al.20 discuss the current status of the
human proteome in terms of the functional characterization of
individual proteins: 1937 proteins have an unknown or
nonspecific function. These are divided into two groups,
1260 of which are PE1 proteins and 677 missing proteins
(PE2,3,4) that also have no function (uMPs). Together, these
are termed “dark proteins”, a phrase first used in the field of
structural genomics (see also HPP definitions: https://hupo.
org/resources/Documents/HPP%20Scientific%20Terms%20
Definitions%20and%20Abbreviations_20180830.pdf). Next,
Paik et al. present a detailed experimental strategy and various
workflows applied to the functionalization of the targeted uPE1
proteins. Starting points depend on individual research teams’
specific expertise and resources and may include protein−
protein interactions with inferences from the known functions
of interacting partners of the uPE1 protein or overexpression
or knockdown/CRISPR Cas9 editing of the target uPE1s. At
present, 15 C-HPP teams, including the newly joined
Chromosome 14 group (led by Charles Pineau, France),
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have initiated plans to characterize three to five uPE1 from
their team’s chromosome. Completion of this will demonstrate
the feasibility and common goal of eventually annotating all
∼2000 dark proteins. As always, this will include contributions
from the entire proteomics community, including the B/D-
HPP and the Pathology Pillar of the HPP. The authors discuss
how the larger characterization initiative will enhance the
understanding of the human proteome and integrated cellular
networks for the discovery of new mechanisms of pathology,
mechanistically informative biomarkers, and rational drug
targets (Figure 1).
As the first report on neXt-CP50, Zhang et al.21 from
Chromosome 17 present an elegant bioinformatics approach in
which a hybrid pipeline using I-TASSER and COFACTOR is
used to predict structures and likely functions of dark proteins.
It is interesting that there are experimental 3D structures for
6188 of the 17 470 PE1 proteins but for only 32 of the 1260
uPE1 proteins. Benchmark testing on a control set of 100 well-
characterized PE1 proteins randomly selected from Chromo-
some 17 showed high Gene Ontology (GO) term prediction
accuracies of 0.69, 0.56, and 0.67 for molecular function (MF),
biological process (BP), and cellular component (CC),
respectively. They applied this tool to all 66 uPE1 proteins
encoded by human Chr 17 as of 2017-08 and utilized GO to
categorize their molecular function for 13, biological process
for 33, and cellular components for 49 based on thresholds
from the benchmarking results. Similar analyses can now be
applied across all of the chromosomes to help guide
experimental studies. This hybrid tool is a novel computational
approach to throw light on yet-to-be-uncovered dark proteins,
with broad applicability to the ∼2000 dark proteins as well as
undefined proteoforms.
Representative of laboratory experimental approaches to
function prediction for uPE1 proteins, Melaine et al.22 from
the French Chromosome 14 team performed LC−MS/MS
analyses of testis protein extracts in combination with public
mRNA and protein expression data. Of 30 identified uPE1
proteins and 15 highly enriched in testis, 2 Chromosome X
proteins (A0AOU1RQG5 and PNMA6E) were subjected to
further analysis. A0AOU1RQG5 contains CT47 domains and
is a putative cancer/testis antigen (CTA) localized and
expressed in the cytoplasm of elongated spermatids, an
immune-privileged site in normal tissue. CTAs appear to be
involved in gametogenesis, sperm metabolism, or motility.
PNMA6E is enriched in the germ cell nuclei during most
stages of spermatogenesis but not in elongated spermatids and
not in Leydig cells. The splice isoform PNMA6E-201 was
identified by 11 non-nested peptides of at least 9 aa, of which 9
are unique to the PNA6E gene and 4 are specific to this
isoform. It is also detected at low levels in the fallopian tube
and ovary. The other 14 members of the PNMA family are
predominantly expressed in the brain. This study demonstrates
that, as in MP studies, testis is a rich source for screening and
characterizing uPE1 dark proteins as well as bringing
enrichment fractionation to detect low-abundance missing
proteins, some of which are currently uMPs. In all, 238
proteins identified in the human testis are uPE1, 19% of the
∼1200 uPE1 proteins in neXtProt. This paper provides a rich
discussion of the approaches to molecular studies of the testis
that may be applicable to many other uPE1 projects.
In another in silico approach to uPE1 proteins, Duek et al.23
(Chromosome 2/14 Switzerland/France) utilized the
SPARQL advanced search functionality of neXtProt to identify
subcellular locations, protein−protein interactions, tissue
expression, disease associations, and 3D structure. A PubMed
search identified characterization papers for 113 of the 2323
uncharacterized proteins; these were considered to already be
engaged in the curation process, so they were excluded. Deep
data mining in various publicly available resources facilitated
functional hypotheses for 26 uPE1 proteins from the fields of
cilia biology, male reproduction, metabolism, nervous system,
immunity, inflammation, RNA metabolism, and chromatin
biology; 13 of the 26 were involved in cilia biology. This paper
shows the power and many applications of neXtProt data and
query tools as well as the desirability of large collaborative
projects involving specialists in different fields of biology.
Functional annotation of the N- and C-termini of all human
proteins in the human proteome is an essential task of the
HPP. Using protein-level dimethylation to label the N-termini,
Marshall et al.24 (Chromosome 6, new U.S./Canadian Team)
were able to purify the N-terminome of both the mitochondria
and corresponding cytosol. Normal cells and those undergoing
early stages of apoptosis prior to caspase-3 activation were also
analyzed by stable isotope labeling by amino acids in cell
culture (SILAC) and terminal amine isotopic labeling of
substrates (TAILS),25 which enabled the largest mitochondrial
N-terminome analysis to date. Together, shotgun and TAILS
identified mature and protease-cleaved neo-amino (N)-termini
of 26% of all mitochondrial proteins and revealed 97 new sites
of proteolysis and 135 novel and 101 known mitochondrial
target sequence cleavage sites that displayed a characteristic
cleavage motif for mitochondrial processing peptidase.
Furthermore, by contributing long ArgC peptides of these
proteins to proteome exchange, TAILS analyses extend MS
coverage of these mitochondrial proteins. These results
implicated specific mitochondrial pathways including protein
import, fission, and iron homeostasis in the initiation of
apoptosis.
Monti et al.26 from the Mitochondria B/D-HPP team (mt-
HPP) update the mitochondrial proteome interactome data-
base (DB) using neXtProt because it incorporates more kinds
of data than MitoCarta 2.0 or the Integrated Mitochondrial
Protein Index. The aim is to obtain an informative functional
network with mitochondrial proteins as nodes and high-quality
binary interactions as edges. Mitochondria are complex
organelles; different functions are associated with distinct
subcompartments (outer membrane, intermembrane space,
inner membrane, matrix). They demonstrate that this DB may
be useful to predict the function or submitochondrial
localization of proteins from the network and to identify
disease proteins of mitochondrial origin. Specifically, they
mapped proteins lacking functional annotation to enhance
speculation on their role through knowledge of their
interactors and investigated mitochondrial proteins in
Parkinson’s disease, in which mitochondrial dysfunction is
thought to be important.
■ PROGRESS ON THE DEVELOPMENT OF
BIOINFORMATICS TOOLS AND MS DATA
ANALYSIS
The development of bioinformatics tools and MS analysis is
essential to promote proteomic studies (Figure 1). Jeong et
al.27 have designed an ASV-ID workflow for predicting
candidate protein alternative splice isoforms that are usually
not easily distinguishable between proteins with highly
homologous peptide sequences. They demonstrate that this
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tool enables the identification of ASVs using a cell-type-specific
protein sequence DB that is supported by RNA-Seq data. They
have identified 1935 distinct proteins under stringent
conditions, which resulted in 19 differently expressed isoforms
present across several cell lines (A549, HEK293, HeLa,
HepFG2, MCF7); IDH2L and IDH2S offer an interesting
example of different isoform expression and different N-
terminal mitochondrial transit function across the cell lines.
These small numbers may be attributed to the fact that this
tool counts only isoforms exhibiting cell-type-specific ex-
pression supported by RNA-sequencing data sets, as the
transcripts can distinguish which of identical sequences may be
expressed. This new workflow may have the potential to map
difficult protein isoforms in a robust way without turning to
the use of multiple proteases to reveal splice junctions.
In 2017, the HPP Bioinformatics Resource Pillar team led by
Eric Deutsch addressed a longstanding need for a tool for
automated detailed comparison of spectra, both observed
versus predicted and observed natural versus observed
synthetic peptides.28 This year, the Proteomics Standards
Initiative reports from the October 2017 Dagstuhl Seminar on
Computational Proteomics and its April 2018 Heidelberg
Workshop a framework for organizing the desired metadata for
spectra using a controlled vocabulary in a spectral library.29
This review addresses four levels of granularity, the library
(collection), the individual peptide ion, the peak fragment ion,
and the peak annotation level, as well as strategies for
comparing spectra, generating representative spectra for a
library, selecting optimal signature ions for targeted workflows,
and merging two or more libraries. The rapid development of
data-independent acquisition (DIA) workflows has spurred
new interest in spectral libraries to analyze extracted ion
chromatograms for peptide ions, whereas targeted workflows
(SRM/PRM) increasingly rely on large-scale spectral libraries
to determine which proteotypic peptides and fragment ions to
monitor. The libraries have lagged far behind the massive
accumulation of data, so these advances are timely. A “gold
standard test data set” is proposed: one spectral library with
10 000 entries from synthetic peptides and one mzML file with
10 000 spectra, in which 5000 peptide ions (but not exact
spectra) are in common.
Sajulga et al.30 describe a versatile bioinformatics tool that
enables a functional connection between C-HPP and B/D-
HPP proteogenomics data sets. This tool is composed of
Galaxy-P and CRAVAT and seems to be quite useful for
assessing data sets obtained from the HPP. The tool uses
“proBed” from the HUPO Proteomics Standards Initiative,
making this open software useful for improved interpretation
of the function and pathological effects of protein sequence
variants detected via proteogenomics. Mendoza et al.31
introduce a very interesting open-source software tool,
ProteoMapper, which enables ultrafast mapping of peptides
to a reference proteome by creating an index for an input
proteome from a FASTA or PEFF file. ProMaST, one of the
key components of this tool, performs fast mapping of input
peptides against the index. Using a fuzzy search function,
ProteoMapper can identify not only sequence variation but
also highly similar peptides (e.g., isobaric or near-isobaric
substitution). It is useful for checking peptide uniqueness,
distinguishing between catalogued and uncatalogued sequence
variations in a protein and across the proteome. Although 90%
of peptides in the Human PeptideAtlas map uniquely to one
gene, complications arise when one gene yields multiple splice
isoforms (several of which may be present simultaneously in a
sample), when peptides map to multiple proteins (in the same
protein family or in repeated motifs in unrelated proteins), and
due to sequence variation (mutations/polymorphisms).
ProteoMapper will enhance compliance with the HPP MS
Data Interpretation Guidelines v2.1.0, which are required for
reports of finding MPs, and facilitate the incorporation of
additional very large data sets into the reanalysis pipeline of
PeptideAtlas.
A particularly notable contribution to the Special Issue is by
Pullman et al.,32 who report the development of “Protei-
nExplorer”, a repository-scale resource for exploration at
MassIVE-KB at UC San Diego. This tool facilitates not only
the systematic reanalysis of public data sets but also the
confirmation of detected novel proteins. Furthermore, it helps
end-users build customized peptide spectral libraries to inspect
novel proteins by crosschecking spectra of synthetic peptides.
A critical aim is to overcome the serious problem that true
matches coincide across most data sets but false matches are
likely to be unique to each data set; therefore, the naıv̈e union
of discovered MPs would result in an uncontrolled increase in
FDRs. This resource tool will enhance MassIVE-KB, which is
connected to ProteomeXchange, and thereby will link in a new
collaboration to PeptideAtlas and neXtProt. This paper
forwards 107 PE2,3,4 MPs for review at PeptideAtlas for the
incorporation into neXtProt. MassIVE-KB currently holds 31
TB of high or higher energy C-trap dissociation (HCD) data
for >1 million unique peptide sequences mapped to >16 000
proteins, expanded further by BioPlex and ProteomeTools
data.
Finally, in the area of methods development for MS analysis,
Ilgisonis et al.33 (Chromosome 18, Russia) report a study
aimed at demonstrating the enhanced sensitivity of targeted
and shotgun LC−MS/MS analysis due to alkaline reverse-
phase (RP) prefractionation of the sample, using results from a
UPS2 standard spiked into E. coli or P. pastoris protein extracts.
■ PROGRESS ON PROTEOMIC STUDIES OF
BIOLOGY AND DISEASE
Glycoproteomics is a very significant subfield of proteomics,
combining complex glycan structures with post-translational
N- and O-glycosylated modifications of the proteins. The
Japanese colleagues have been pioneers in glycoproteomics
and leaders of the HPP efforts in this domain. Narimatsu et
al.34 extensively review current technologies, including
improved sensitivity and speed of mass spectrometry, new
software for complex spectrum assignment, a unique approach
to identify intact glycopeptides using MS1-based accurate
masses, and spatial distribution within cells using MS imaging
and lectin microarray. There are many applications to biology
and disease. An important observation is that glycan structures
are cell-specific and hence are good candidates for biomarkers.
Boersema et al.35 from the B/D-HPP Protein Aggregation
Diseases initiative discuss recent advances in our knowledge of
protein aggregation diseases (PADs). PADs are characterized
by the intracellular and extracellular accumulation of
aggregated proteins, as commonly seen in Parkinson’s,
Alzheimer’s, and Huntington’s diseases, ALS, amyloidosis,
and frontotemporal dementia. Each disease has distinctive
protein aggregates. Their team has been active in developing
MS-based proteomics approaches, which would be useful for
clinical diagnosis through the quantification of aggregation-
prone proteins to support both basic and clinical research.
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Proteins are known to undergo aberrant conformational
transitions, leading to misfolding and aggregation. The group
has developed protein extraction protocols and MS methods to
detect and quantify proteins involved in systemic and localized
amyloidosis and probing of the conformation transitions in
cells and tissue extracts. Assay coordinates are shared through
public repositories and databases. There is a good network
between clinicians and proteomics investigators for improving
methods for early diagnosis and subtyping these devastating
diseases.
Wang et al.36 provide a deep analysis of the cysteine
oxidative proteome in cardiac hypertrophy, a key feature of
hypertensive heart disease, congestive heart failure, and sudden
cardiac death. Reactive oxygen and nitrogen species (RS/NS)
mediate hypertrophy through multiple types of oxidation of
protein cysteine residues, triggering molecular switches. The
major cysteine O-PTMs are reversible S-nitrosylation, S-
glutationylation, sulfenic acid, disulfide bonds, and S-
sulfhydration, plus irreversible sulfinic acid (CysSO2H) or
sulfonic acid (CysSO3H). The Van Eyk and Ping laboratories
have developed assays specific for these chemistries. Here they
combine a customized biotin switch-based quantitative
proteomics pipeline with an analytic workflow using cubic
spline-based temporal clustering to characterize the dynamic
hypertrophy landscape in an isoproterenol-induced mouse
model. They identified 2505 protein containing 6818 cysteine
sites, with 1655 proteins with 3324 sites modified by at least
one of three cysteine O-PTM types. They also discuss
mechanisms of cardio protection.
Naryzhny et al.37 report an updated version of their virtual
2DE proteome map based on the analysis of several cell lines
(HepG2, glioblastoma, LEH, HEK), normal liver, and plasma,
which was coupled to shotgun mass spectrometry using LC−
ESI−MS/MS. They claim confident identification of informa-
tion (minimum of two significant sequences) about the
proteoforms of 117 isoforms coded by 104 genes of
Chromosome 18, awaiting additional study for validation.
During the past 2 to 3 years, two groups have exploited
bibliometric analyses to identify “popular proteins” for the B/
D-HPP teams and for the global community.38,39 These are
proteins that have been studied extensively and reported
frequently, for which multiplex-targeted proteomics could
provide a potent approach to quantitation and biological
insights. Advances in DIA, such as MS-SWATH, could
accelerate progress. Many B/D-HPP teams are utilizing the
organ-specific popular proteins lists. Yu et al.40 now extend this
approach to targeted metabolomics and biochemical studies.
Text mining for metabolites and chemicals is hindered by
numerous synonyms and nonstandard names. Here they use
cloud-based literature mining to connect copublication trends
of metabolites/chemicals and B/D-HPP topics using Protein
Universal Reference Publication-Originated Search Engine
(PURPOSE) scores. Note the use of PURPOSE in the report
by Boeresma et al. from the B/D-HPP PAD team.35 Lau et
al.41 identify high-priority proteins across the human
diseaseome using semantic similarity between a protein and
a query term in the biomedical literature. They adjust for
impact and recency of the articles across cell types,
subanatomical regions, and standardized vocabularies with
20 000 disease terms. Reverse protein-to-disease analyses
might be useful for the neXt-CP50 Challenge to predict and
experimentally demonstrate the functions of uPE1 proteins.
■ CONCLUSIONS
The HUPO HPP stimulates and coordinates analyses of high-
quality data for the whole field of proteomics. The resource
pillars of the HPP, including PeptideAtlas, neXtProt,
ProteomeXchange/PRIDE, and Human Protein Atlas provide
a unifying foundation for the field and for proteogenomic and
multiomics analyses in all disease categories.
This sixth annual special issue of the Journal of Proteome
Research documents the remarkable progress in detecting and
validating the expression of predicted human proteins, with
17 470 of the neXtProt PE1,2,3,4 predicted proteins now PE1
(89%), signifying compelling evidence at the protein level.
Progress on the PE2,3,4 MP Challenge is documented here,
and the new challenge to characterize the functions of 1260
presently unannotated PE1 proteins is introduced in
substantial depth. Additional papers address bioinformatics
tools and then a wide range of applications to studies of
biological processes and particular diseases.
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Economıá y Competitividad to F.C.), ProteoRed, PRB2-
ISCIII, PT13/0001L, and PRB3-ISCIII PT17/0019 (Spanish
Institutes of Health ISCIII to F.C.). We thank Jin-Young Cho
and Chae-Yeon Kim for their assistance in the preparation of
this manuscript
■ REFERENCES
(1) Omenn, G. S.; Lane, L.; Overall, C. M.; Corrales, F. J.; Schwenk,
J. M.; Paik, Y. K.; Van Eyk, J. E.; Liu, S.; Snyder, M.; Baker, M. S.;
Deutsch, E. W. Progress on Identifying and Characterizing the
Human Proteome: 2018 Metrics from the HUPO Human Proteome
Project. J. Proteome Res. 2018, DOI: 10.1021/acs.jproteome.8b00441.
(2) Macron, C.; Lane, L.; Nunez Galindo, A.; Dayon, L.
Identification of Missing Proteins in Normal Human Cerebrospinal
Fluid. J. Proteome Res. 2018, DOI: 10.1021/acs.jproteome.8b00194.
(3) Deutsch, E. W.; Overall, C. M.; Van Eyk, J. E.; Baker, M. S.; Paik,
Y. K.; Weintraub, S. T.; Lane, L.; Martens, L.; Vandenbrouck, Y.;
Kusebauch, U.; Hancock, W. S.; Hermjakob, H.; Aebersold, R.;
Moritz, R. L.; Omenn, G. S. Human Proteome Project Mass
Spectrometry Data Interpretation Guidelines 2.1. J. Proteome Res.
2016, 15 (11), 3961−3970.
(4) Macron, C.; Lane, L.; Nunez Galindo, A.; Dayon, L. Deep Dive
on the Proteome of Human Cerebrospinal Fluid: A Valuable Data
Resource for Biomarker Discovery and Missing Protein Identification.
J. Proteome Res. 2018, DOI: 10.1021/acs.jproteome.8b00300.
(5) Hwang, H.; Jeong, J. E.; Lee, H. K.; Yun, K. N.; An, H. J.; Lee,
B.; Paik, Y. K.; Jeong, T. S.; Yee, G. T.; Kim, J. Y.; Yoo, J. S.
Identification of Missing Proteins in Human Olfactory Epithelial
Tissue by Liquid Chromatography−Tandem Mass Spectrometry. J.
Proteome Res. 2018, DOI: 10.1021/acs.jproteome.8b00408.
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(7) Clemente, L. F.; Hernaéz, M. L.; Ramos-Fernandez, A.; Ligero,
G.; Gil, C.; Corrales, F. J.; Marcilla, M. Identification of the Missing
Protein Hyaluronan Synthase 1 in Human Mesenchymal Stem Cells
Derived from Adipose Tissue or Umbilical Cord. J. Proteome Res.
2018, DOI: 10.1021/acs.jproteome.8b00384.
(8) Weldemariam, M. M.; Han, C. L.; Shekari, F.; Kitata, R. B.;
Chuang, C. Y.; Hsu, W. T.; Kuo, H. C.; Choong, W. K.; Sung, T. Y.;
He, F. C.; Chung, M. C. M.; Salekdeh, G. H.; Chen, Y. J. Subcellular
Proteome Landscape of Human Embryonic Stem Cells Revealed
Missing Membrane Proteins. J. Proteome Res. 2018, DOI: 10.1021/
acs.jproteome.8b00407.
(9) Zhang, Y.; Lin, Z.; Hao, P.; Hou, K.; Sui, Y.; Zhang, K.; He, Y.;
Li, H.; Yang, H.; Liu, S.; Ren, Y. Improvement of Peptide Separation
for Exploring the Missing Proteins Localized on Membranes. J.
Proteome Res. 2018, DOI: 10.1021/acs.jproteome.8b00409.
(10) Robin, T.; Bairoch, A.; Muller, M.; Lisacek, F.; Lane, L. Large-
Scale Reanalysis of Publicly Available HeLa Cell Proteomics Data in
the Context of the Human Proteome Project. J. Proteome Res. 2018,
DOI: 10.1021/acs.jproteome.8b00392.
(11) Ronci, M.; Pieroni, L.; Greco, V.; Scotti, L.; Marini, F.;
Carregari, V. C.; Cunsolo, V.; Foti, S.; Aceto, A.; Urbani, A.
Sequential Fractionation Strategy Identifies Three Missing Proteins in
the Mitochondrial Proteome of Commonly Used Cell Lines. J.
Proteome Res. 2018, DOI: 10.1021/acs.jproteome.8b00422.
(12) Vandenbrouck, Y.; Lane, L.; Carapito, C.; Duek, P.; Rondel, K.;
Bruley, C.; Macron, C.; Gonzalez de Peredo, A.; Coute, Y.; Chaoui,
K.; Com, E.; Gateau, A.; Hesse, A. M.; Marcellin, M.; Mear, L.;
Mouton-Barbosa, E.; Robin, T.; Burlet-Schiltz, O.; Cianferani, S.;
Ferro, M.; Freour, T.; Lindskog, C.; Garin, J.; Pineau, C. Looking for
Missing Proteins in the Proteome of Human Spermatozoa: An
Update. J. Proteome Res. 2016, 15 (11), 3998−4019.
(13) Carapito, C.; Duek, P.; Macron, C.; Seffals, M.; Rondel, K.;
Delalande, F.; Lindskog, C.; Freour, T.; Vandenbrouck, Y.; Lane, L.;
Pineau, C. Validating Missing Proteins in Human Sperm Cells by
Targeted Mass-Spectrometry- and Antibody-based Methods. J.
Proteome Res. 2017, 16 (12), 4340−4351.
(14) Zhang, Y.; Li, Q.; Wu, F.; Zhou, R.; Qi, Y.; Su, N.; Chen, L.;
Xu, S.; Jiang, T.; Zhang, C.; Cheng, G.; Chen, X.; Kong, D.; Wang, Y.;
Zhang, T.; Zi, J.; Wei, W.; Gao, Y.; Zhen, B.; Xiong, Z.; Wu, S.; Yang,
P.; Wang, Q.; Wen, B.; He, F.; Xu, P.; Liu, S. Tissue-Based
Proteogenomics Reveals that Human Testis Endows Plentiful Missing
Proteins. J. Proteome Res. 2015, 14 (9), 3583−94.
(15) Wang, Y.; Chen, Y.; Zhang, Y.; Wei, W.; Li, Y.; Zhang, T.; He,
F.; Gao, Y.; Xu, P. Multi-Protease Strategy Identifies Three
PE2Missing Proteins in Human Testis Tissue. J. Proteome Res.
2017, 16 (12), 4352−4363.
(16) Sun, J.; Shi, J.; Wang, Y.; Chen, Y.; Li, Y.; Kong, D.; Chang, L.;
Liu, F.; Lv, Z.; Zhou, Y.; He, F.; Zhang, Y.; Xu, P. Multiproteases
Combined with High-pH Reverse-Phase Separation Strategy Verified
Fourteen Missing Proteins in Human Testis Tissue. J. Proteome Res.
2018, DOI: 10.1021/acs.jproteome.8b00397.
(17) He, C.; Sun, J.; Shi, J.; Wang, Y.; Zhao, J.; Wu, S.; Chang, L.;
Gao, H.; Liu, F.; Lv, Z.; He, F.; Zhang, Y.; Xu, P. Digging for Missing
Proteins Using Low-Molecular-Weight Protein Enrichment and a
“Mirror Protease” Strategy. J. Proteome Res. 2018, DOI: 10.1021/
acs.jproteome.8b00398.
(18) Huesgen, P. F.; Lange, P. F.; Rogers, L. D.; Solis, N.; Eckhard,
U.; Kleifeld, O.; Goulas, T.; Gomis-Rüth, F. X.; Overall, C. M.
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